We are live on
!
Find out more
MU
Mirova US Portfolio holdings
AUM
$8.81B
1-Year Est. Return
21.38%
This Fund
S&P 500
This Quarter
Est. Return
+11.23%
1 Year Est. Return
+21.38%
3 Year Est. Return
+80.7%
5 Year Est. Return
+106.85%
10 Year Est. Return
–
AUM
$4.98B
AUM Growth
+$697M
(+16%)
Cap. Flow
+$242M
Cap. Flow
% of AUM
4.87%
Top 10 Holdings %
Top 10 Hldgs %
59.82%
Holding
31
New
2
Increased
23
Reduced
6
Closed
–
Top Buys
| 1 |
SIVB
SVB Financial Group
SIVB
|
+$158M |
| 2 |
NVIDIA
NVDA
|
+$94M |
| 3 |
AGCO
AGCO
|
+$76.3M |
| 4 |
eBay
EBAY
|
+$75.6M |
| 5 |
Thermo Fisher Scientific
TMO
|
+$8.69M |
Top Sells
| 1 |
Eli Lilly
LLY
|
+$70.1M |
| 2 |
Mercado Libre
MELI
|
+$64.9M |
| 3 |
Deere & Co
DE
|
+$34.7M |
| 4 |
Mastercard
MA
|
+$23.3M |
| 5 |
Visa
V
|
+$17.9M |
Sector Composition
| 1 | Technology | 27.02% |
| 2 | Healthcare | 20.33% |
| 3 | Financials | 17.25% |
| 4 | Consumer Discretionary | 11.34% |
| 5 | Industrials | 7.74% |
Similar funds
MERSOM
CFB
MOACM
SWP
CB
WT
OAM
PEA
Mirova US's Q4 2022 Portfolio in Review
As of Q4 2022, Mirova US held 31 positions worth $4.98B, up 16% from $4.28B the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Mirova US deployed $242M of net new capital in Q4 2022, opening 2 new positions and adding to 23 existing holdings. Its largest new stake was AGCO: 618,588 shares worth $85.8M.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 26% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Eli Lilly, an estimated $70.1M trimmed.
- Mirova US's largest Q4 2022 buy was AGCO: 618,588 shares worth $85.8M.
- Mirova US added most to SVB Financial Group in Q4 2022, an estimated $158M increase.
- Mirova US's biggest Q4 2022 reduction was Eli Lilly, cutting an estimated $70.1M.
- Mirova US's ten largest holdings make up 60% of its $4.98B portfolio in Q4 2022.
- Mirova US opened 2 new positions and closed 0 in Q4 2022.
- Mirova US's portfolio value rose 16% quarter-over-quarter to $4.98B.
Based on Mirova US's 13F filing for Q4 2022, filed 9 Feb 2023.